- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Nautilus Biotechnology Inc (NAUT)
The Nautilus Biotechnology share price today is 0.865, view NASDAQ NAUT stock exchange data. Track the latest Nautilus Biotechnology share price with real-time updates on NAUT stock performance including market cap, day range, 52-week range and dividend yield. Access NAUT charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.860
0.970
52 wk Range
0.620
4.310
NAUT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.8600.970
52 wk Range
0.6204.310
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NAUT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
4.000
Upside
+362.43%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 4.000
(+362.43% Upside)
Nautilus Biotechnology Inc Earnings Call Summary for Q2/2026
- Nautilus posted Q2 2026 adjusted loss of $0.11/share, beating consensus estimate of $0.15/share by 26.67%; revenue reached $0.2M vs. $0 forecast.
- Company shifted R&D focus to proteoform assays from Broadscale program; operating expenses fell 7% YoY to $15.9M amid tighter cost controls.
- Cash position of $129.2M provides runway into Q1 2028; management expects capital raise between now and mid-2027 through debt and equity mix.
- Maintained 2026 revenue guidance at $0.5M; Voyager platform pre-orders to open early 2027, instrument shipments targeted for mid-2027 at ~$1M price.
- Shares fell 3.49% to $1.602 in premarket despite earnings beat; analysts maintain $4 price target, citing commercialization and funding risks.
Last Updated: 28-07-2026, 06:58 pm
Read Full TranscriptEarnings
Latest Release
28-07-2026
EPS / Forecast
-0.11 / -0.15
Revenue / Forecast
190K / --
Compare NAUT to Peers and Sector
Metrics to compare | NAUT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNAUTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.9x | −4.3x | −0.4x | |
PEG Ratio | −0.13 | −0.11 | 0.00 | |
Price/Book | 0.8x | 1.3x | 2.6x | |
Price / LTM Sales | 579.3x | 7.8x | 3.1x | |
Upside (Analyst Target) | 362.4% | 29.0% | 48.2% | |
Fair Value Upside | Unlock | 14.4% | 5.8% | Unlock |
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Nautilus Biotechnology (NAUT) Share Price Today?
The Nautilus Biotechnology share price today is 0.865.
What is the current Nautilus Biotechnology (NAUT) share price and day range?
As of 11-08-2026, the Nautilus Biotechnology share price is 0.865, with a previous close of 0.865. The share price has ranged from 0.860 to 0.970 today, while the 52-week range spans from 0.620 to 4.310.
What Is the Nautilus Biotechnology Market Cap?
As of today, Nautilus Biotechnology market cap is 110.080M.
What Is the Nautilus Biotechnology (NAUT) Share Price Target?
The average 12-month share price target for Nautilus Biotechnology is 4.000, with a high estimate of 4 and a low estimate of 4. 2 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +362.43% Upside potential.
What Is Nautilus Biotechnology's Earnings Per Share (TTM)?
The Nautilus Biotechnology EPS (TTM) is -0.446.
When Is the Next Nautilus Biotechnology Earnings Date?
Nautilus Biotechnology will release its next earnings report on 03-11-2026.
From a Technical Analysis Perspective, Is NAUT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Nautilus Biotechnology Trade On?
Nautilus Biotechnology is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Nautilus Biotechnology?
The stock symbol for Nautilus Biotechnology is "NAUT."
How Many Times Has Nautilus Biotechnology Stock Split?
Nautilus Biotechnology has split 0 times.
How Many Employees Does Nautilus Biotechnology Have?
Nautilus Biotechnology has 127 employees.
What Is the NAUT Premarket Price?
NAUT's last pre-market stock price is 0.900. The pre-market share volume is 450.000, and the stock has changed by 0.035, or 4.050%.
What Is the NAUT After Hours Price?
NAUT's last after hours stock price is 0.886, the stock has changed by 0.021, or 2.370%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.